Rural Maryland-based biotechnology business seeks to develop new methods for image-based tissue diagnostics and assays
COLUMBIA, Md., (August 27, 2024) — 
TEDCO, Maryland’s economic engine for technology companies, announced a recent $25,000 Pre-Seed Rural Business Innovation Initiative (RBII) investment in NEOPATHOLOGY CORP. TEDCO’s RBII was designed to enhance technology commercialization and provide technical and business assistance to small and early-stage companies based in rural Maryland.
“Our proprietary approach standardizes the tissue diagnostic process using contemporary spatial biology-enabling platforms,” said Paul Aiyetan, founder, CEO and director of NEOPATHOLOGY CORP. “Through this process, we are hoping to reduce diagnostic errors, improve diagnostic accuracy and expedite the time to treatment initiation. Thanks to TEDCO’s investment, we can continue progressing towards our goals.”
NEOPATHOLOGY CORP., located in Frederick, Md., is a biotechnology research and clinical diagnostic company developing more accurate and rapidly reported primarily image-based tissue diagnostics and assays. 
Its proprietary diagnostic process ONEPATHOLOGY™, an end-to-end learning solution seeks to standardize advanced spatial biology and contemporary deep-tissue profiling technologies utility and clinical adoption.
“Dr. Aiyetan’s innovative thinking proves why TEDCO’s RBII program exists – to further the research and development happening in rural Maryland,” said Karen Zuccardi, manager for TEDCO’s RBII. “We hope with this investment, NEOPATHOLOGY finds more success in bringing their platform to the market.”
For more information about mentoring and funding opportunities from the RBII program, please visit https://www.tedcomd.com/resources/rural-business-innovation-initiative.